Name
Osaühing ProtoBioS
Registry code
10981915
VAT number
EE100875737
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
03.11.2003 (21)
Financial year
01.01-31.12
Capital
2 550.00 €
Activity
72111 - Research and experimental development on biotechnology
-
-
-
-
-
-
Not submitted
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Omanikukonto: TÕNIS TIMMUSK 07.01.1959 (65) | 10% - 255.00 EUR | - | Direct ownership | Founder |
| Kaia Palm 13.05.1964 (60) | 85% - 2 168.00 EUR | Board member | Direct ownership | Founder |
| Omanikukonto: TOOMAS NEUMAN 22.04.1953 (71) | 5% - 127.00 EUR | - | Direct ownership | Founder |
| Marko Piirsoo 19.06.1974 (50) | - | - | - | Founder |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| IPDx Diagnostics OÜ 14261017 | 64% - 2 415.00 EUR | - | - | Founder |
| Osaühing FibroTx 11183541 | 18% - 14 400.00 EUR | - | - | Founder |
| Biolaborid OÜ 11879691 | - | - | - | Founder |
| OÜ Cellin Technologies 11543666 | - | - | - | Founder |
| 2019 30.10.2020 | 2020 21.01.2022 | 2021 06.07.2022 | 2022 03.07.2023 | |
|---|---|---|---|---|
| Total Revenue | 137 654 € | 34 473 € | 5 922 € | 0 € |
| Net profit (loss) for the period | -21 413 € | 6 764 € | 2 658 € | 4 089 € |
| Profit Margin | -16% | 20% | 45% | - |
| Current Assets | 359 446 € | 411 225 € | 538 746 € | 1 094 266 € |
| Fixed Assets | 802 218 € | 726 877 € | 641 483 € | 553 936 € |
| Total Assets | 1 161 664 € | 1 138 102 € | 1 180 229 € | 1 648 202 € |
| Current Liabilities | 374 257 € | 343 931 € | 385 789 € | 319 412 € |
| Non Current Liabilities | - | - | - | 530 260 € |
| Total Liabilities | - | - | - | 849 672 € |
| Share Capital | - | - | - | - |
| Equity | 787 407 € | 794 171 € | 794 440 € | 798 530 € |
| Employees | 14 | 7 | 6 | 7 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 25 766.98 € | 42 780.37 € | 46 014.68 € | 12 |
| 2023 Q4 | 15 590.7 € | 43 279.73 € | 46 526.3 € | 15 |
| 2023 Q3 | 2 500 € | 34 102.8 € | 36 601.14 € | 14 |
| 2023 Q2 | 4 920 € | 32 120.89 € | 34 454.46 € | 13 |
| 2023 Q1 | 456.81 € | 26 929.85 € | 28 742.63 € | 11 |
| 2022 Q4 | - | 29 927.62 € | 32 147.89 € | 12 |
| 2022 Q3 | 64.8 € | 22 803.61 € | 24 601.29 € | 11 |
| 2022 Q2 | 3 077.95 € | 23 436.02 € | 25 168.44 € | 14 |
| 2022 Q1 | 30 735 € | 24 027.42 € | 26 010.38 € | 14 |
| 2021 Q4 | 3 662 € | 18 523.86 € | 19 758.4 € | 13 |
| 2021 Q3 | 4 404.93 € | 21 379.36 € | 23 121.89 € | 12 |
| 2021 Q2 | - | 23 040.18 € | 24 907.81 € | 13 |
| 2021 Q1 | 8 364.39 € | 24 476.76 € | 26 549.17 € | 13 |
| 2020 Q4 | - | 22 800.13 € | 24 757.88 € | 15 |
| 2020 Q3 | - | 21 332.84 € | 23 166.77 € | 14 |
| 2020 Q2 | 9 813.3 € | 27 543.57 € | 28 743.07 € | 14 |
| 2020 Q1 | 49 983.82 € | 37 343.07 € | 33 213.72 € | 15 |
